Hello, everybody. My name is Martin. I'm the CEO of Xbrane, and I'm here together with Jane, our CFO. We will go through the highlights of our Q1 report 2026. I will start with an operational update, and Jane will thereafter go through the financials.
So we will start with Ximluci, our Lucentis biosimilar. And we will then go through some highlights in relation to Xdivane, our Opdivo biosimilar candidate. On the development, Ximluci has been launched across 24 countries in Europe and the Middle East, and it's a product which we have partnered with. STADA is commercializing the product across these different countries, and it's a quite simple setup where we share the profit contribution, post-production costs and sales and marketing expenses. 5050. And it's a sizable addressable market.
If we look at it as anti-VEGF products for retinal disorders. We have, of course, then Lucentis and the Lucentis biosimilars. That's the dark blue chunk in the bottom of this graph on the left-hand side.
Active ingredient ranibizumab.
And then we have other competing molecules Eylea and Vabysmo and some off-label usage of the cancer drug Avastin.
But all in all, a market opportunity of €5 billion, which is growing on the back of an elderly population driving increased need for this kind of drugs.
And also, to some extent, more cost-efficient options coming to the market within the ranibizumab or Lucentis biosimilars, with a particular focus now on Ximluci and its performance last quarter. Important to note is that we have a constant cash profit sharing coming in in Q1 2026 in relation to fourth quarter of 2025.
So we'll see a little bit later in the presentation, when Jane goes through the cash flow, that we had 13 million Swedish crowns coming in as cash this quarter. And that was from the fourth quarter. And we'll have a similar amount as a result of sales this quarter.
But the volumes have gone down slightly compared to last quarter. But it's a result of a focus on maintaining profit margin level and maintaining the profit contribution in a market where we actually are seeing prices going down and a quite high degree of price competitiveness within this market segment.
And we are, as we've talked about before, going through several measures to reduce our production cost.
And we believe that that is going to bear fruit in 2027 and onwards. And our estimation is that that can unlock further volume growth for us, but for now, we are going to have to focus on maintaining the profit margin with the current production cost that we have. We still have an inventory of mainly drug substance, which we are now gradually converting into cash as we are shipping more product to our partner STADA, and that will take place during the course of this year and next year. So it's 170 million Swedish crowns, which we expect to gradually be converted into cash.
Then US, we released a press release last week; we resubmitted the BLA to FDA. As you might recall, we had a Complete Response Letter in October last year, and that was due to one of our contract manufacturers having unresolved observations from an inspection performed by the FDA during last year. And that site has now worked through those observations and has submitted the documentation to the FDA, where all the actions in relation to the observations have been finalized and the related documentation submitted to the FDA. So, we now expect a regulatory timeline of six months. And we'll have to wait and see whether FDA chooses to reinspect this specific site or not. And we'll have to get back when we know the specific decision date from the FDA.
And the activities leading up to that decision are underway.
Then, shifting gears to Xdivane®, an Opdivo® biosimilar candidate, we're quite excited about this program actually. It is going according to plan towards regulatory submission to the US FDA in the second half of 2027 to enable an approval in the second half of 2028 and an ability to launch the product in early 2029, provided, of course, a timely approval. And that is the point in time when the patent on Opdivo expires. It's an ongoing clinical trial. Recruitment is going according to plan. And we're also in parallel going through all related CMC activities, specifically process characterization and validation of both drug substance and drug product processes, which is also worth mentioning. We are working with a well-established contract manufacturer for this program with a long history of supplying commercial pharmaceutical products to the US and having successfully gone through FDA inspections for related products. So we feel quite comfortable in that we have reduced that development risk, if you will, having learned quite a bit from our Ximluci program. In relation to financing of the development activities. We released a press release this morning where we have agreed with our partner Intas in relation to financing on specific CMC related activities which are under Xbrane responsibility and were, under the original license agreement, Xbrane's financing responsibility. Now, Intas has agreed to partly finance these activities, and that will take place during the course of this and next year and will accrue with an 18% annual add-on on these respective expenses they are paying for. And then, when we are entitled to profit sharing once the product is on the market, those expenses will be deducted prior to Xbrane receiving any profit sharing in connection with this. Intas has also been granted an option to make a one-time lump sum payment corresponding to 40 months of forecasted profit sharing, and they can do that at any point in time during the course of the license. And if they were to do so, that would then release them from the obligation of paying Xbrane any further profit sharing from sales of the product.
However, we do have a period from this point and six months ahead where, if we were to be able to arrange other suitable financing, we could essentially repay whatever Intas would have paid at that point in time and then reverse this option to make the one-time lump sum payment.
So that's the essence of this arrangement.
And in connection with this, we also engaged a company called Venture Valuation AG, an expert in valuing pharmaceutical products. And they had a look on the prospects of Xdivane. They, under the fundamental assumption that the product is approved and could be launched beginning of 2029 in the US and upon European patent expiration mid-2030. They made what they thought were reasonable assumptions with regard to overall market opportunity, biosimilar volume penetration, price discounts and market share of Xdivane. Looking at how oncology biosimilars have developed historically in the US, the level of expected competition for this specific molecule, and so on and so forth. And then applying the profit sharing levels, which Xbrane is entitled to from this program.
And, um, and came to, uh, let's call it the base case, um, with over the course of ten years from 29 to 20, 38, accumulated profit sharing of close to 10 billion Swedish crowns, out of which, um, a third, uh, would be related to first four years. And if you take that expected profit sharing during the course of these four years and calculate a net present value at the beginning of 29 using a 15% discount rate, you end up at 4.4 billion Swedish crowns. So we did this valuation in connection with this amendment, which was done with Intas. And it's to give some kind of guidance. guidance on what 40 months of profit sharing could be worth should that one-time lump sum payment option be exercised by Intas as I described on the last slide. So I think that was the essence from an operational perspective. And we can then shift over to the financials. So I hand over to Jane.